PPD introduces new centralized computing platform for analysis and reporting of clinical trial data

PPD, Inc. (NASDAQ: PPDI) today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company’s ability to deliver secure, quality reporting and data analysis to meet client timelines.

The virtual server environment allows PPD to deploy global teams of biostatisticians and programmers to projects on a single platform. The analysis processing environments are located in the same data centers as PPD's clinical data management systems, eliminating the need to move large quantities of data between file servers. Operating on this unified platform reduces bandwidth utilization, increases employee productivity and creates significant time savings.

“This new environment allows our employees around the world to work together, accessing the same data,” said Susan Atkinson, senior vice president, global biometrics and technical operations for PPD. "Our investment in a global, innovative solution decreases our computer processing time and enhances our data security, giving us the ability to deliver more efficiently for our clients.”

In addition, the BTI features a number of best practice global solutions such as code development, version control, output configuration, validation and delivery of production output. PPD has installed the BTI at its U.S. locations in Austin, Texas, and Research Triangle Park, N.C., as well as at its European headquarters in Cambridge, U.K.